Healthcare entity
Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. The 154-day window averages about 0.2 stories each week.
Last mentioned: 2d ago
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 40 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 26% negative, this entity's 0% share is less negative. They are less corroborated than the beat average, carrying 2 original sources each against 3.7 for the same window. The 154-day window averages about 0.2 stories each week. Their average consequence score of 5.4 runs below the beat's 6 for that window. Briefing.com is the most frequent co-covered peer, appearing in 1 of the 5 tracked stories. The clearest coverage concentration is market-trends: 2 of 5 stories, with the rest divided among 3 other categories. Nasdaq appears in 5 tracked Healthcare stories published from March 13, 2026 through August 13, 2026.
Computed from the 5 stories linked to this entity, with beat comparisons drawn from all 751 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Nasdaq. Shared-story counts are live from our verified record — not editorial picks.
Valion Bio announces technical assessment underway
Valion Bio issued a press release stating the Ministry has begun technical assessment and issued a first round of questions on physicochemical characterization.
Ukraine MOH accepts Entolimod dossier
Ukraine's Ministry of Health accepted Valion Bio's regulatory dossier for Entolimod for formal review under the Regulatory Equivalence Pathway.
Financial Reporting
Lifeward scheduled to report Q4 and full-year 2025 financial results.
Shareholder Approval
Lifeward shareholders vote in favor of the strategic partnership with Oramed.
Nasdaq Compliance
Lifeward regains compliance with Nasdaq minimum bid price requirements.
Ukraine's Ministry of Health has moved Valion Bio's Entolimod dossier into technical assessment, a step toward what would be the drug's first national registration as an acute radiation syndrome countermeasure. The company says a decision could come as early as Q4 2026, though no procurement or stockpiling agreement exists.
Source: hawaiitelegraph.com · finanznachrichten.de
SNDL’s completion of the Parallel asset acquisition gives it indirect control of medical cannabis operations in three states, positioning the company to directly expand patient access and standardize products once Nasdaq consolidation is achieved.
Source: stockhouse.com · thestarphoenix.com
Heartflow (NASDAQ: HTFL) reported a significant 40.5% year-over-year revenue increase in its latest quarterly results, though earnings per share fell short of analyst expectations. The company posted a loss of $0.29 per share, missing the consensus estimate of $0.16 as it continues to invest heavily in market expansion.
Source: Zolmax · Daily Political
Hologic, Inc. (NASDAQ: HOLX) has experienced a dramatic 71.7% increase in short interest, signaling a significant shift in investor sentiment toward the medical technology leader. This surge suggests growing skepticism regarding the company's near-term growth prospects in its core women's health and diagnostics segments.
Source: tickerreport.com · dailypolitical.com
Lifeward Ltd shareholders have officially approved a strategic partnership with Oramed Pharmaceuticals, signaling a major pivot toward becoming a diversified biomedical company. The deal integrates Lifeward's robotic rehabilitation technology with Oramed's pharmaceutical expertise to create a multi-disciplinary healthcare entity.
Source: finanznachrichten.de · manilatimes.net
Nasdaq is linked from 5 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
